Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 3, 2007, Pages 303-311

  Patel, Nick C ^a,b   Hariparsad, Monica ^b   Matias Akthar, Mary ^c   Sorter, Michael T ^c   Barzman, Drew H ^c   Morrison, John A ^c   Stanford, Kevin E ^a   Strakowski, Stephen M ^a   DelBello, Melissa P ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOZAPINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; LIPID; LITHIUM; LOW DENSITY LIPOPROTEIN; METHYLPHENIDATE; MOOD STABILIZER; OLANZAPINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADOLESCENT; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; BIPOLAR DISORDER; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; DEMOGRAPHY; DEPRESSION; DEVELOPMENTAL DISORDER; DYSLIPIDEMIA; ETHNICITY; FEMALE; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL DISEASE; OBESITY; POLYPHARMACY; PREVALENCE; STATISTICAL ANALYSIS; SUBSTANCE ABUSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MENTAL DISORDERS; OBESITY; PILOT PROJECTS; PREVALENCE;

EID: 34447542797     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0037     Document Type: Article

References (24)

1. American Diabetes Association, American Psychiatric Association; American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DM-IV-TR), 2000.
3. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J: Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 58:589-594, 2005.
4. Boyd GS, Koenigsberg J, Falkner B, Gidding S, Hassink S: Effect of obesity and high blood pressure on plasma lipid levels in children and adolescents. Pediatrics 116:442-446, 2005.
5. Brown S, Birtwistle J, Roe L, Thompson C: The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697-701, 1999.
6. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindemayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH: Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65(Suppl 7):4-18, 2004.
7. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH: Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 157:821-827, 2003.
8. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791, 2006.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001.
10. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291:2847-2850, 2004.
11. Kociancic T, Reed MD, Findling RL: Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children. Expert Opinion Drug Safety 3:93-100, 2004.
12. Kopf D, Westphal S, Luley CW, Ritter S, Gilles M, Weber-Hamann B, Lederbogen F, Lehnert H, Henn FA, Heuser I, Deuschle M: Lipid metabolism and insulin resistance in depressed patients: Significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol 24:527-531, 2004.
13. Martin A, L'Ecuyer S: Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry 11:129-133, 2002.
14. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH: The disease burden associated with overweight and obesity. JAMA 282:1523-1529, 1999.
15. National Cholesterol Education Program Coordinating Committee: Report of the Expert Panel on Blood Cholesterol in Children and Adolescents (NIH publication 91-2732). Bethesda (Maryland): National Heart, Lung, and Blood Institute, 1991.
16. Ogden CL, Flegal KM, Carroll MD, Johnson CL: Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 288:1728-1732, 2002.
17. Pappadopulos E, Jensen PS, Schur SB, MacIntyre JC 2nd, Ketner S, Van Orden K, Sverd J, Sardana S, Woodlock D, Schweitzer R, Rube D: "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 28:111-121, 2002.
18. Patel NC, Crismon ML, Hoagwood K, Jensen PS: Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J Child Adolesc Psychopharmacol 15:270-284, 2005.
19. Sachs GS, Guille C: Weight gain associated with use of psychotropic medications. J Clin Psychiatry 60(Suppl 21):16-19, 1999.
20. Safer DJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24: 429-436, 2004.
21. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL: Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721-730, 2006.
22. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004.
23. Stigler KA, Potenza MN, Posey DJ, McDougle CJ: Weight gain associated with atypical antipsychotic use in children and adolescents: Prevalence, clinical relevance, and management. Paediatr Drugs 6:33-44, 2004.
24. Vieweg WV, Kuhnley LJ, Kuhnley EJ, Anum EA, Sood B, Pandurangi A, Silverman JJ: Body mass index (BMI) in newly admitted child and adolescent psychiatric inpatients. Prog Neuropsychopharmacol Biol Psychiatry 29:511-515, 2005.